SCHEMBL166844

SCHEMBL166844

O=C(O)c1cccc(C(=O)N2CCCC2c2cccnc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
KDM4E B2RXH2 3/20 0.65
SCD O00767 1/20 0.54
ROCK2 O75116 1/20 0.54
TDP1 Q9NUW8 3/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53
BLM P54132 1/20 0.51
ALOX15 P16050 1/20 0.51
GPBAR1 Q8TDU6 1/20 0.49
CHRNA7 P36544 2/20 0.49
CHRNB2 P17787 2/20 0.49
CHRNB4 P30926 2/20 0.49
CHRNA3 P32297 2/20 0.49
CHRNA4 P43681 2/20 0.49
CHRNA2 Q15822 2/20 0.49
LMNA P02545 1/20 0.49
HTR3E A5X5Y0 1/20 0.49
PSIP1 O75475 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165005 0.87 SCD (0.55) ALDH1A1KDM4ESCDROCK2
SCHEMBL166098 0.87 KDM4E (0.66) ALDH1A1KDM4ESCDROCK2TDP1
SCHEMBL164387 0.86 PARP14 (0.60) SCDROCK2
(+/-)Nicotine SCHEMBL31028378 0.85 ALDH1A1 (0.71) ALDH1A1KDM4ETDP1MEN1HPGD
SCHEMBL17888397 0.81 ALDH1A1 (0.59) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL21078063 0.81 ALDH1A1 (0.64) ALDH1A1KDM4ETDP1MEN1HPGD
SCHEMBL5909347 0.79 ALDH1A1 (0.59) ALDH1A1KDM4ETDP1BLMALOX15
(+/-)Nicotine SCHEMBL17291841 0.79 KDM4E (0.65) ALDH1A1KDM4ETDP1MEN1HPGD
Nicotine SCHEMBL17291839 0.79 KDM4E (0.65) ALDH1A1KDM4ETDP1MEN1HPGD
SCHEMBL17886675 0.78 ALDH1A1 (0.56) ALDH1A1KDM4ESCDTDP1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611441-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2013-07-10 EP disclosed
CN-103079562-A BACE inhibitors for use in the treatment of diabetes HOFFMANN LA ROCHE 2013-05-01 CN disclosed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 WO disclosed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 WO disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053200-A1 BACE 2 INHIBITORS BACE2, BACE1, PSEN2 ALDH1A1 756/4885KDM4E 2480/4885SCD 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.